Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
600
Trial Collaborator
Clinical Trial Start Date
July 1, 2024
0Primary Completion Date
February 1, 2026
0Study Completion Date
July 1, 2026
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Other0
Interventional Trial Phase
Phase 20
Official Name
A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome0
Last Updated
March 13, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Investigator0
Participant0
Care Provider0
Outcomes Assessor0
Other attributes
Intervention Treatment
MRG-001 (High-dose)0
MRG-001 (Low-dose)0
Placebo0
Study summary
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
